The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An insight into the challenges in prolonging remission in AML
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the challenges in prolonging remission in patients with acute myeloid leukemia (AML). Currently, azacitidine plus venetoclax or hypomethylating agents (HMA) plus venetoclax are used to prolong patients’ remission and survival, and research aims to develop a triplet therapy regimen that would improve outcomes further. However, this must be done while limiting additional hematological toxicity and optimizing sequencing and timing of treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is a good question too. So today, for the elderly patient, the aim is, of course, to prolong remission and to prolong the survival of the patient. Today we are with the classical treatment with azacitidine plus venetoclax or HMA plus venetoclax, and we are working to develop some triplets to add other drugs or other targeted therapies. But there is not too much place to add some hematological toxicity in this patient for a long time if the duration of remission is long...
So this is a good question too. So today, for the elderly patient, the aim is, of course, to prolong remission and to prolong the survival of the patient. Today we are with the classical treatment with azacitidine plus venetoclax or HMA plus venetoclax, and we are working to develop some triplets to add other drugs or other targeted therapies. But there is not too much place to add some hematological toxicity in this patient for a long time if the duration of remission is long.
So for me, I think this is the challenge to find the good triplets or maybe to find the good sequence to use all these treatments efficiently in acute myeloid leukemia, and maybe to find the good time to use the treatment, at diagnosis, at relapse, together or not.
Read more...
Disclosures
Abbvie, BMS, Jazz, Servier, Novartis, Syros.
